0821 GMT - U.S. president Trump's pro-innovation stance could boost new drug discoveries, Novartis chief executive officer Vas Narasimhan tells CNBC at the World Economic Forum in Davos. "The Biden administration put in place some policies with the Inflation Reduction Act that were pretty damaging for the innovation ecosystem," Narasimhan says. Biden's IRA included Medicare's drug-price negotiation law, widely seen as negative by the industry. While the nomination of vaccine-skeptic Robert F. Kennedy Jr. to lead the country's health department poses a challenge for the sector, Narasimhan emphasizes the need to find common ground with the new administration, especially on preventing diseases like cancer and heart attacks. "There's obviously areas of disagreement, but I think overall, this is actually going to be a better environment for us than the past four years," Narasimhan says. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 21, 2025 03:21 ET (08:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。